Logo image of NICE

NICE LTD - SPON ADR (NICE) Stock Fundamental Analysis

NASDAQ:NICE - US6536561086 - ADR

138.64 USD
-2.01 (-1.43%)
Last: 8/26/2025, 8:00:01 PM
138.5 USD
-0.14 (-0.1%)
After Hours: 8/26/2025, 8:00:01 PM
Fundamental Rating

6

Taking everything into account, NICE scores 6 out of 10 in our fundamental rating. NICE was compared to 282 industry peers in the Software industry. NICE scores excellent on profitability, but there are some minor concerns on its financial health. NICE is valued quite cheap, while showing a decent growth score. This is a good combination! These ratings would make NICE suitable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

NICE had positive earnings in the past year.
NICE had a positive operating cash flow in the past year.
Each year in the past 5 years NICE has been profitable.
NICE had a positive operating cash flow in each of the past 5 years.
NICE Yearly Net Income VS EBIT VS OCF VS FCFNICE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

1.2 Ratios

Looking at the Return On Assets, with a value of 10.06%, NICE belongs to the top of the industry, outperforming 86.88% of the companies in the same industry.
NICE's Return On Equity of 14.31% is amongst the best of the industry. NICE outperforms 81.91% of its industry peers.
Looking at the Return On Invested Capital, with a value of 11.37%, NICE belongs to the top of the industry, outperforming 87.59% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for NICE is below the industry average of 11.98%.
The last Return On Invested Capital (11.37%) for NICE is above the 3 year average (8.49%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 10.06%
ROE 14.31%
ROIC 11.37%
ROA(3y)6.78%
ROA(5y)5.84%
ROE(3y)10.34%
ROE(5y)9.15%
ROIC(3y)8.49%
ROIC(5y)7.35%
NICE Yearly ROA, ROE, ROICNICE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

Looking at the Profit Margin, with a value of 18.81%, NICE belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
NICE's Profit Margin has improved in the last couple of years.
The Operating Margin of NICE (21.39%) is better than 87.59% of its industry peers.
In the last couple of years the Operating Margin of NICE has grown nicely.
NICE has a Gross Margin of 67.03%. This is comparable to the rest of the industry: NICE outperforms 46.81% of its industry peers.
In the last couple of years the Gross Margin of NICE has remained more or less at the same level.
Industry RankSector Rank
OM 21.39%
PM (TTM) 18.81%
GM 67.03%
OM growth 3Y13.23%
OM growth 5Y5.7%
PM growth 3Y15.65%
PM growth 5Y6.35%
GM growth 3Y-0.37%
GM growth 5Y0.16%
NICE Yearly Profit, Operating, Gross MarginsNICE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NICE is creating some value.
Compared to 1 year ago, NICE has more shares outstanding
NICE has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, NICE has an improved debt to assets ratio.
NICE Yearly Shares OutstandingNICE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NICE Yearly Total Debt VS Total AssetsNICE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

NICE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.7
Altman-Z N/A
ROIC/WACC1.26
WACC9.06%
NICE Yearly LT Debt VS Equity VS FCFNICE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

A Current Ratio of 1.83 indicates that NICE should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.83, NICE is in line with its industry, outperforming 58.16% of the companies in the same industry.
A Quick Ratio of 1.83 indicates that NICE should not have too much problems paying its short term obligations.
NICE has a Quick ratio (1.83) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.83
NICE Yearly Current Assets VS Current LiabilitesNICE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

6

3. Growth

3.1 Past

NICE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.59%, which is quite good.
NICE shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.93% yearly.
Looking at the last year, NICE shows a quite strong growth in Revenue. The Revenue has grown by 11.39% in the last year.
Measured over the past years, NICE shows a quite strong growth in Revenue. The Revenue has been growing by 11.69% on average per year.
EPS 1Y (TTM)19.59%
EPS 3Y19.48%
EPS 5Y15.93%
EPS Q2Q%14.02%
Revenue 1Y (TTM)11.39%
Revenue growth 3Y12.5%
Revenue growth 5Y11.69%
Sales Q2Q%9.38%

3.2 Future

NICE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.40% yearly.
Based on estimates for the next years, NICE will show a quite strong growth in Revenue. The Revenue will grow by 8.30% on average per year.
EPS Next Y14.15%
EPS Next 2Y11.75%
EPS Next 3Y12.4%
EPS Next 5YN/A
Revenue Next Year7.22%
Revenue Next 2Y7.11%
Revenue Next 3Y8.3%
Revenue Next 5YN/A

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NICE Yearly Revenue VS EstimatesNICE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1B 2B 3B
NICE Yearly EPS VS EstimatesNICE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5 10 15

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 11.71, the valuation of NICE can be described as very reasonable.
Based on the Price/Earnings ratio, NICE is valued cheaper than 87.94% of the companies in the same industry.
NICE's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.08.
With a Price/Forward Earnings ratio of 9.93, the valuation of NICE can be described as very reasonable.
NICE's Price/Forward Earnings ratio is rather cheap when compared to the industry. NICE is cheaper than 90.78% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.67. NICE is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.71
Fwd PE 9.93
NICE Price Earnings VS Forward Price EarningsNICE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NICE indicates a rather cheap valuation: NICE is cheaper than 91.84% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, NICE is valued cheaply inside the industry as 92.20% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.2
EV/EBITDA 8.09
NICE Per share dataNICE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of NICE may justify a higher PE ratio.
NICE's earnings are expected to grow with 12.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.83
PEG (5Y)0.73
EPS Next 2Y11.75%
EPS Next 3Y12.4%

More info and screens

0

5. Dividend

5.1 Amount

NICE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NICE LTD - SPON ADR

NASDAQ:NICE (8/26/2025, 8:00:01 PM)

After market: 138.5 -0.14 (-0.1%)

138.64

-2.01 (-1.43%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)08-14 2025-08-14/dmh
Earnings (Next)11-12 2025-11-12/bmo
Inst Owners11.94%
Inst Owner Change-5.56%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap8.72B
Analysts81.33
Price Target200.14 (44.36%)
Short Float %4.27%
Short Ratio4.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1.29%
Min EPS beat(2)-1.41%
Max EPS beat(2)-1.17%
EPS beat(4)1
Avg EPS beat(4)0.63%
Min EPS beat(4)-1.41%
Max EPS beat(4)5.16%
EPS beat(8)5
Avg EPS beat(8)1.44%
EPS beat(12)9
Avg EPS beat(12)1.55%
EPS beat(16)12
Avg EPS beat(16)1.75%
Revenue beat(2)0
Avg Revenue beat(2)-1.05%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-0.14%
Revenue beat(4)0
Avg Revenue beat(4)-1.12%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)-0.14%
Revenue beat(8)0
Avg Revenue beat(8)-1.21%
Revenue beat(12)0
Avg Revenue beat(12)-1.25%
Revenue beat(16)3
Avg Revenue beat(16)-0.49%
PT rev (1m)-4.99%
PT rev (3m)-3.78%
EPS NQ rev (1m)-1.48%
EPS NQ rev (3m)-1.5%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)-0.7%
Revenue NQ rev (1m)-1.06%
Revenue NQ rev (3m)-3.69%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)0.17%
Valuation
Industry RankSector Rank
PE 11.71
Fwd PE 9.93
P/S 3.07
P/FCF 13.2
P/OCF 11.55
P/B 2.34
P/tB 5.21
EV/EBITDA 8.09
EPS(TTM)11.84
EY8.54%
EPS(NY)13.96
Fwd EY10.07%
FCF(TTM)10.5
FCFY7.57%
OCF(TTM)12.01
OCFY8.66%
SpS45.15
BVpS59.35
TBVpS26.62
PEG (NY)0.83
PEG (5Y)0.73
Profitability
Industry RankSector Rank
ROA 10.06%
ROE 14.31%
ROCE 15.46%
ROIC 11.37%
ROICexc 19.46%
ROICexgc 188.31%
OM 21.39%
PM (TTM) 18.81%
GM 67.03%
FCFM 23.26%
ROA(3y)6.78%
ROA(5y)5.84%
ROE(3y)10.34%
ROE(5y)9.15%
ROIC(3y)8.49%
ROIC(5y)7.35%
ROICexc(3y)14.21%
ROICexc(5y)12.54%
ROICexgc(3y)163.28%
ROICexgc(5y)N/A
ROCE(3y)11.55%
ROCE(5y)10%
ROICexcg growth 3Y25.64%
ROICexcg growth 5Y53.44%
ROICexc growth 3Y23.73%
ROICexc growth 5Y18.38%
OM growth 3Y13.23%
OM growth 5Y5.7%
PM growth 3Y15.65%
PM growth 5Y6.35%
GM growth 3Y-0.37%
GM growth 5Y0.16%
F-Score7
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.7
Debt/EBITDA 0
Cap/Depr 49.93%
Cap/Sales 3.34%
Interest Coverage 250
Cash Conversion 94.72%
Profit Quality 123.61%
Current Ratio 1.83
Quick Ratio 1.83
Altman-Z N/A
F-Score7
WACC9.06%
ROIC/WACC1.26
Cap/Depr(3y)48.45%
Cap/Depr(5y)43.32%
Cap/Sales(3y)3.65%
Cap/Sales(5y)3.66%
Profit Quality(3y)152.88%
Profit Quality(5y)173.68%
High Growth Momentum
Growth
EPS 1Y (TTM)19.59%
EPS 3Y19.48%
EPS 5Y15.93%
EPS Q2Q%14.02%
EPS Next Y14.15%
EPS Next 2Y11.75%
EPS Next 3Y12.4%
EPS Next 5YN/A
Revenue 1Y (TTM)11.39%
Revenue growth 3Y12.5%
Revenue growth 5Y11.69%
Sales Q2Q%9.38%
Revenue Next Year7.22%
Revenue Next 2Y7.11%
Revenue Next 3Y8.3%
Revenue Next 5YN/A
EBIT growth 1Y21.29%
EBIT growth 3Y27.38%
EBIT growth 5Y18.06%
EBIT Next Year17.62%
EBIT Next 3Y9.19%
EBIT Next 5YN/A
FCF growth 1Y49.42%
FCF growth 3Y22.92%
FCF growth 5Y18.61%
OCF growth 1Y42.08%
OCF growth 3Y21.71%
OCF growth 5Y17.35%